Oral Anticoagulants in the Treatment of Venous Thromboembolic Complications: Focus on Apixaban

Medical Council
doi 10.21518/2079-701x-2017-4-56-62
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Remedium, Ltd.

Related search

Oral Apixaban for the Treatment of Acute Venous Thromboembolism

Journal of Vascular Surgery
SurgeryCardiovascular MedicineCardiology
2014English

The Treatment of Venous Thromboembolism With New Oral Anticoagulants

Italian Journal of Medicine
Medicine
2013English

Application of a New Peroral Anticoagulants in Treatment and Prophylaxis of Thromboembolic Complications

Klinicheskaia khirurgiia
MedicineSurgery
2019English

New Oral Antithrombotics: Focus on Dabigatran, an Oral, Reversible Direct Thrombin Inhibitor for the Prevention and Treatment of Venous and Arterial Thromboembolic Disorders

Vascular Health and Risk Management
2012English

A Cost-Effectiveness Analysis of Novel Oral Anticoagulants for Primary Prevention of Venous Thromboembolic Disease

Value in Health
MedicineHealth PolicyPublic HealthOccupational HealthEnvironmental
2015English

Novel Anticoagulants for Thromboembolic Complications Prevention in Nonvalvular Atrial Fibrillation

Russian Journal of Cardiology
Cardiovascular MedicineCardiology
2015English

Bleeding Complications From the Direct Oral Anticoagulants

BMC Hematology
HematologyMolecular Biology
2015English

Recent Advances in the Treatment of Venous Thromboembolism in the Era of the Direct Oral Anticoagulants

F1000Research
GeneticsMolecular BiologyPharmacologyBiochemistryMicrobiology ImmunologyMedicineToxicologyPharmaceutics
2017English

New Oral Anticoagulants for the Treatment of Venous Thromboembolism: Understanding Differences and Similarities

Drugs
Pharmacology
2014English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy